FDA, MDA Establish Common Principles For AI in Medicine Development

The integration of AI technologies into the pharmaceutical lifecycle has gained momentum, particularly with proposals from the European Commission's Biotech Act that emphasize AI's role in expediting drug development and regulatory processes. This new legislative framework supports testing innovative AI-driven methods, aiming to enhance the safety and effectiveness of medicines while fostering innovation. Effective management of these technologies is crucial to mitigate risks as AI continues to evolve, ensuring compliance with safety standards. Collaboration between the European Medicines Agency and the U.S. FDA reflects a commitment to advancing these initiatives and shaping future regulations in the healthcare technology landscape.

Opens on EMA